the propel clinical trial exploring olaparib plus abiraterone in mcrpc
Published 2 years ago • 550 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
5:36
propel trial
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
1:19
highlights in prostate cancer from esmo
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
4:02
novel parpi arpi therapeutic combinations in 1l mcrpc: findings from clinical trials
-
1:39
challenges in the field of parpi treatment for mcrpc
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
8:31
recent updates in prostate cancer: stampede, vision & profound
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc